The spatial distribution of receptors and the bypassing of ligands could, however, substantially affect the success of such targeted therapies, which is exemplified by the apparent failures of IGF-1R inhibitors in cancer patients [22, 51]. This evidence concerns the gene IGF1R and cancer.